The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2'-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes.

[1]  Wenbin Liu,et al.  Mycoplasma hyorhinis infection in gastric carcinoma and its effects on the malignant phenotypes of gastric cancer cells , 2010, BMC gastroenterology.

[2]  K. Mills,et al.  Phosphoramidates of 2′-β-d-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism , 2010, Bioorganic & Medicinal Chemistry.

[3]  J. Balzarini,et al.  Aryloxy Phosphoramidate Triesters: a Technology for Delivering Monophosphorylated Nucleosides and Sugars into Cells , 2009, ChemMedChem.

[4]  A. Brancale,et al.  The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. , 2009, Journal of medicinal chemistry.

[5]  I. Nagtegaal,et al.  A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? , 2009, European journal of cancer.

[6]  J. Balzarini,et al.  Improvement of purine and pyrimidine antimetabolite-based anticancer treatment by selective suppression of mycoplasma-encoded catabolic enzymes. , 2009, The Lancet. Oncology.

[7]  F. Gago,et al.  The dual role of thymidine phosphorylase in cancer development and chemotherapy , 2009, Medicinal research reviews.

[8]  J. Balzarini,et al.  The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: Implications for cancer therapy. , 2008, Biochemical pharmacology.

[9]  H. Birnboim,et al.  Resistance of colorectal cancer cells to 5-FUdR and 5-FU caused by Mycoplasma infection. , 2008, Anticancer research.

[10]  M. Erion,et al.  Prodrugs of phosphates and phosphonates. , 2008, Journal of medicinal chemistry.

[11]  G. La Torre,et al.  Predictive Role of Thymidylate Synthase, Dihydropyrimidine Dehydrogenase and Thymidine Phosphorylase Expression in Colorectal Cancer Patients Receiving Adjuvant 5-Fluorouracil , 2007, Oncology.

[12]  M. Mason,et al.  Novel potential anticancer naphthyl phosphoramidates of BVdU: separation of diastereoisomers and assignment of the absolute configuration of the phosphorus center. , 2006, Journal of medicinal chemistry.

[13]  M. Ochiai,et al.  Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. , 2005, Oncology reports.

[14]  William A. Lee,et al.  Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue , 2005, Antimicrobial Agents and Chemotherapy.

[15]  H. Onay,et al.  Can mycoplasma-mediated oncogenesis be responsible for formation of conventional renal cell carcinoma? , 2005, Urology.

[16]  S. Takashima,et al.  Effects of thymidine phosphorylase levels in cancer, background mucosa, and regional lymph nodes on survival of advanced gastric cancer patients receiving postoperative fluoropyrimidine therapy. , 2004, Oncology reports.

[17]  G. Peters,et al.  Role of Platelet Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase in Fluoropyrimidine Sensitivity and Potential Role of Deoxyribose‐1‐Phosphate , 2004, Nucleosides, nucleotides & nucleic acids.

[18]  H. Bulut,et al.  Does Mycoplasma sp. play role in small cell lung cancer? , 2004, Lung cancer.

[19]  P. Cuq,et al.  Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story. , 2004, Current medicinal chemistry. Anti-cancer agents.

[20]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[21]  J. Mackey,et al.  Nucleoside analogues and nucleobases in cancer treatment. , 2002, The Lancet. Oncology.

[22]  E. De Clercq,et al.  Synthesis and Antiviral Evaluation of Phosphoramidate Derivatives of (E)-5-(2-Bromovinyl)-2′-Deoxyuridine , 2001, Antiviral chemistry & chemotherapy.

[23]  C. Shou,et al.  Mycoplasma infections and different human carcinomas. , 2001, World journal of gastroenterology.

[24]  M. Fukushima,et al.  The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents. , 2000, Current pharmaceutical biotechnology.

[25]  N. Suzuki,et al.  Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. , 2000, International journal of oncology.

[26]  R. Agarwal,et al.  Collateral resistance of a dideoxycytidine-resistant cell line to 5-fluoro-2'-deoxyuridine. , 1999, Biochemical and biophysical research communications.

[27]  E. De Clercq,et al.  Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. , 1999, Biochemical pharmacology.

[28]  Y. Naot,et al.  Molecular Biology and Pathogenicity of Mycoplasmas , 1998, Microbiology and Molecular Biology Reviews.

[29]  W. Patton,et al.  Assessment of archived paraffin-embedded cervical condyloma tissues for mycoplasma-conserved DNA using sensitive PCR-ELISA. , 1998, Gynecologic oncology.

[30]  H. Ishitsuka,et al.  Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. , 1998, Biochemical pharmacology.

[31]  E. De Clercq,et al.  Phosphoramidate derivatives of d4T as inhibitors of HIV: the effect of amino acid variation. , 1997, Antiviral research.

[32]  P. Chan,et al.  Prevalence of mycoplasma conserved DNA in malignant ovarian cancer detected using sensitive PCR-ELISA. , 1996, Gynecologic oncology.

[33]  E. De Clercq,et al.  Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. , 1996, Journal of medicinal chemistry.

[34]  T. Sugimura,et al.  Presence of Streptococcus DNA Sequence in Surgical Specimens of Gastric Cancer , 1995, Japanese journal of cancer research : Gann.

[35]  L. Montagnier,et al.  Identification of Mycoplasma pirum genes involved in the salvage pathways for nucleosides , 1993, Journal of bacteriology.

[36]  E. De Clercq,et al.  Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT. , 1993, Journal of medicinal chemistry.

[37]  Y. Rustum,et al.  Mechanisms of resistance to fluoropyrimidines. , 1992, Seminars in oncology.

[38]  J. Bertino,et al.  Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine in the HCT-8 human carcinoma line. , 1985, Cancer research.

[39]  E. De Clercq,et al.  Strategies for the measurement of the inhibitory effects of thymidine analogs on the activity of thymidylate synthase in intact murine leukemia L1210 cells. , 1984, Biochimica et biophysica acta.

[40]  L. R. Finch,et al.  Enzymes of pyrimidine deoxyribonucleotide metabolism in Mycoplasma mycoides subsp. mycoides , 1983, Journal of Bacteriology.

[41]  R. T. Walker,et al.  Role of thymidine kinase in the inhibitory activity of 5-substituted-2'-deoxyuridines on the growth of human and murine tumor cell lines. , 1982, Biochemical pharmacology.

[42]  J. Charron,et al.  Analysis of deoxycytidine (dC) deaminase activity in herpes simplex virus-infected or HSV TK-transformed cells: association with mycoplasma contamination but not with virus infection. , 1981, The Journal of general virology.

[43]  C. Walko,et al.  Capecitabine: a review. , 2005, Clinical therapeutics.

[44]  G. Milano,et al.  A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. , 1994, European journal of cancer.

[45]  F. Sinigaglia,et al.  Inhibition of [3H]thymidine incorporation by Mycoplasma arginini‐infected cells due to enzymatic cleavage of the nucleoside , 1985, European journal of immunology.

[46]  S. Razin.  The mycoplasmas. , 1978, Microbiological reviews.